Significant Improvement in Detecting BRAF KRAS and EGFR Mutations Using Next-Generation Sequencing as Compared with FDA-Cleared Kits

摘要

IntroductionWe compared mutations detected in EGFR, KRAS, and BRAF genes using next-generation sequencing (NGS) and confirmed by Sanger sequencing with mutations that could be detected by FDA-cleared testing kits.